Her2/neu sensitized dendritic cell vaccine (Haixin Biotechnology)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameHer2/neu sensitized dendritic cell vaccine (Haixin Biotechnology)

Drug Alias NameN/A

ClassificationVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccineVaccines > Application > Therapeutic vaccine

Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 modulators

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaPending

Originator CompaniesShanghai Haixin Bio-Tech Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesShanghai Haixin Bio-Tech Co Ltd

Active IndicationsN/A

Inactive IndicationsBreast Neoplasms

Other Information

ATC CodeN/A